Erschienen in:
01.08.2013 | Original Article
The Efficacy and Safety of Neoadjuvant Chemotherapy in Treatment of Locally Advanced Carcinoma Cervix
verfasst von:
Uma Singh, Neetu Ahirwar, Anju Kumari Rani, Nisha Singh, Pushplata Sankhwar, Sabuhi Qureshi
Erschienen in:
The Journal of Obstetrics and Gynecology of India
|
Ausgabe 4/2013
Einloggen, um Zugang zu erhalten
Abstract
Objective
A prospective cohort study in a teaching hospital to assess the efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced carcinoma cervix.
Method
Neoadjuvant chemotherapy in the form of cisplatin 75 mg/m2 and paclitaxel 135 mg/m2 on day 1 and repeated at 14 days’ interval for up to a maximum of three courses.
Results
Neoadjuvant chemotherapy in cervical cancer was effective in the downstaging of the disease. Downstaging was observed in 19.23 % of patients after two cycles and in 50 % of patients after three cycle of NACT. Operability increases to 33.3 and 38.4 % after two and three cycles of NACT, respectively. Complete pathological response was observed in 37.5 % of patients after NACT. No significant adverse effect in the feasibility of surgery was observed.
Conclusion
The present study showed that neoadjuvant chemotherapy was an effective and well-tolerated mode of therapy with significantly less morbidity and mortality.